Hutchmed to Withdraw Cancer Drug in China

MT Newswires Live

Mar 09

Hutchmed (HCM) said Monday it has initiated the withdrawal and recall of Tazverik in mainland China, Hong Kong and Macau after Ipsen decided to voluntarily withdraw the drug from the US market.

The company said Ipsen infomred it that the decision followed a review of emerging data from the phase 1b/3 trial in follicular lymphoma.

An independent data monitoring committee concluded that risks may outweigh benefits for patients in the treatment regimen, the company said, citing Ipsen.

Hutchmed said it has suspended sales and shipments of the drug, notified healthcare institutions to stop prescribing it and pharmacies to cease dispensing it, and is discontinuing all active tazemetostat clinical trials in China.

Hutchmed said the withdrawal is not expected to affect its financial guidance, noting that sales of Tazverik totaled about $2.5 million in 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2618486642"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618486642\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618486642?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 18:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618486642","market":"fut","top_or_hot":-1,"title":"Hutchmed to Withdraw Cancer Drug in China","media":"MT Newswires Live","content":"<html><body><p> Hutchmed (HCM) said Monday it has initiated the withdrawal and recall of Tazverik in mainland China, Hong Kong and Macau after Ipsen decided to voluntarily withdraw the drug from the US market.</p><p>The company said Ipsen infomred it that the decision followed a review of emerging data from the phase 1b/3 trial in follicular lymphoma.</p><p>An independent data monitoring committee concluded that risks may outweigh benefits for patients in the treatment regimen, the company said, citing Ipsen.</p><p>Hutchmed said it has suspended sales and shipments of the drug, notified healthcare institutions to stop prescribing it and pharmacies to cease dispensing it, and is discontinuing all active tazemetostat clinical trials in China.</p><p>Hutchmed said the withdrawal is not expected to affect its financial guidance, noting that sales of Tazverik totaled about $2.5 million in 2025.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hutchmed to Withdraw Cancer Drug in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHutchmed to Withdraw Cancer Drug in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-09 18:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hutchmed (HCM) said Monday it has initiated the withdrawal and recall of Tazverik in mainland China, Hong Kong and Macau after Ipsen decided to voluntarily withdraw the drug from the US market.</p><p>The company said Ipsen infomred it that the decision followed a review of emerging data from the phase 1b/3 trial in follicular lymphoma.</p><p>An independent data monitoring committee concluded that risks may outweigh benefits for patients in the treatment regimen, the company said, citing Ipsen.</p><p>Hutchmed said it has suspended sales and shipments of the drug, notified healthcare institutions to stop prescribing it and pharmacies to cease dispensing it, and is discontinuing all active tazemetostat clinical trials in China.</p><p>Hutchmed said the withdrawal is not expected to affect its financial guidance, noting that sales of Tazverik totaled about $2.5 million in 2025.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618486642","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618486642","pubTimestamp":1773051037,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hutchmed  said Monday it has initiated the withdrawal and recall of Tazverik in mainland China, Hong Kong and Macau after Ipsen decided to voluntarily withdraw the drug from the US market.The company said Ipsen infomred it that the decision followed a review of emerging data from the phase 1b/3 trial in follicular lymphoma.An independent data monitoring committee concluded that risks may outweigh benefits for patients in the treatment regimen, the company said, citing Ipsen.Hutchmed said it has suspended sales and shipments of the drug, notified healthcare institutions to stop prescribing it and pharmacies to cease dispensing it, and is discontinuing all active tazemetostat clinical trials in China.Hutchmed said the withdrawal is not expected to affect its financial guidance, noting that sales of Tazverik totaled about $2.5 million in 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4531":"中概回港概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","HCM":"和黄医药"},"translate_title":"和黄医药将在中国撤回抗癌药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCM":1},"content_text":"Hutchmed (HCM) said Monday it has initiated the withdrawal and recall of Tazverik in mainland China, Hong Kong and Macau after Ipsen decided to voluntarily withdraw the drug from the US market.The company said Ipsen infomred it that the decision followed a review of emerging data from the phase 1b/3 trial in follicular lymphoma.An independent data monitoring committee concluded that risks may outweigh benefits for patients in the treatment regimen, the company said, citing Ipsen.Hutchmed said it has suspended sales and shipments of the drug, notified healthcare institutions to stop prescribing it and pharmacies to cease dispensing it, and is discontinuing all active tazemetostat clinical trials in China.Hutchmed said the withdrawal is not expected to affect its financial guidance, noting that sales of Tazverik totaled about $2.5 million in 2025.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}